Brief: Consun Pharmaceutical Group Posts FY Profit Attributable Of RMB79.8 Mln
March 23 (Reuters) - Consun Pharmaceutical Group Ltd
1681.HK :
* BOARD PROPOSED TO DECLARE A FINAL DIVIDEND OF HKD0.10 PER
SHARE
* FY REVENUE DOWN 6.3% TO RMB1.73 BILLION
* PROFIT FOR YEAR ATTRIBUTABLE RMB79.8 MLN, DOWN 82.8%
* ESTIMATED TRIAL PRODUCTION OF HUASHENGXIAN TO BE COMPLETED
IN
2020 & WILL APPLY FOR COMMENCEMENT OF CLINICAL STUDY
* OFFERS TREATMENTS FOR RESPIRATORY DISEASES, HENCE HAS
OPTIMISTIC
OUTLOOK FOR CHINESE MEDICINE MARKET & CHINESE MEDICINE COS
Source text for Eikon: ID:nHKS7h7m3p
Further company coverage: 1681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Consun Pharmaceutical
See all newsChina's Consun Pharmaceutical H1 revenue rises on sales network expansion
Brief: Consun Pharmaceutical Says Unit To Invest RMB191.4 Mln In Shanghai Huamao Pharmaceutical
Brief: Consun Pharmaceutical Group Announces Share Repurchase Program Up To HKD200 Million
Brief: Consun Pharmaceutical Logs FY Revenue RMB 3,420 Mln
Brief: Consun Pharmaceutical Says Executive Director Zhu Quan Redesignated As Non-Executive Director